Eli Lilly's Brenipatide Shows Early Promise for Substance Use and Psychiatric Disorders

Eli Lilly has reported early positive clinical data for its GIP/GLP-1 receptor agonist candidate brenipatide, supporting once-weekly dosing in treating substance use, psychiatric, and immunologic disorders. The company also outlined Phase III trial designs to evaluate the drug's efficacy in major depressive disorder and alcohol use disorder. This announcement marks a significant step in the development of new treatments for these challenging conditions.

Originally published by gnews